| 001 | 283219 | ||
| 005 | 20260116093029.0 | ||
| 024 | 7 | _ | |a 10.1007/s00117-025-01541-y |2 doi |
| 024 | 7 | _ | |a pmid:41348123 |2 pmid |
| 024 | 7 | _ | |a 2731-7048 |2 ISSN |
| 024 | 7 | _ | |a 0033-832X |2 ISSN |
| 024 | 7 | _ | |a 1432-2102 |2 ISSN |
| 024 | 7 | _ | |a 2731-7056 |2 ISSN |
| 037 | _ | _ | |a DZNE-2026-00068 |
| 041 | _ | _ | |a German |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Neumann, Timotheus Josef |b 0 |
| 245 | _ | _ | |a Bildgebung neurologischer Nebenwirkungen unter Immuntherapien : Immuncheckpoint-Inhibitoren und CAR-T-Zellen | Imaging of neurological adverse events associated with immunotherapies : Immune checkpoint inhibitors and CAR-T cells |
| 260 | _ | _ | |a [Berlin] |c 2026 |b Springer Medizin Verlag GmbH |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1768552061_4733 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Immune checkpoint inhibitors (ICI) and chimeric antigen receptor T‑cell (CAR-T) therapies have fundamentally transformed oncology. With their increasing use, immune-related adverse events (irAEs) have gained attention, including those affecting the nervous system.To describe the clinical and imaging characteristics of neurological immune-related adverse events (NirAEs) under ICI and CAR‑T therapy, as well as their differential diagnostic and therapeutic implications.Review of current literature on the incidence, clinical spectrum, and imaging features of NirAEs.NirAEs occur in approximately 1-6% of patients treated with ICIs. Common manifestations include myositis, myasthenic syndromes, peripheral neuropathies, and various forms of encephalitis, which may differ clinically and radiologically from their idiopathic or paraneoplastic counterparts. Under CAR‑T therapy, immune effector cell-associated neurotoxicity syndrome (ICANS) represents the most frequent neurotoxic complication and affects about 30% of patients. Magnetic resonance imaging (MRI) is the imaging modality of choice but often reveals nonspecific or initially unremarkable findings. A pretherapeutic baseline MRI and close imaging follow-up improve diagnostic interpretation and prognostic assessment. Findings must always be interpreted within the clinical context and through interdisciplinary collaboration.NirAEs are rare but potentially life-threatening. Due to unspecific imaging findings and overlapping differential diagnoses, close interdisciplinary cooperation between radiology, neurology, and oncology is essential. Early recognition and imaging follow-up are key to improving prognosis and survival. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Central and peripheral nervous system |2 Other |
| 650 | _ | 7 | |a ICANS (immune effector cell–associated neurotoxicity syndrome) |2 Other |
| 650 | _ | 7 | |a Magnetic resonance imaging |2 Other |
| 650 | _ | 7 | |a Neuroradiological diagnostics |2 Other |
| 650 | _ | 7 | |a Neurotoxicity under immunotherapy |2 Other |
| 650 | _ | 7 | |a Immune Checkpoint Inhibitors |2 NLM Chemicals |
| 650 | _ | 7 | |a Receptors, Chimeric Antigen |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Immune Checkpoint Inhibitors: adverse effects |2 MeSH |
| 650 | _ | 2 | |a Immune Checkpoint Inhibitors: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a Immunotherapy, Adoptive: adverse effects |2 MeSH |
| 650 | _ | 2 | |a Magnetic Resonance Imaging: methods |2 MeSH |
| 650 | _ | 2 | |a Neurotoxicity Syndromes: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Neurotoxicity Syndromes: etiology |2 MeSH |
| 650 | _ | 2 | |a Immunotherapy: adverse effects |2 MeSH |
| 650 | _ | 2 | |a Nervous System Diseases: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Nervous System Diseases: chemically induced |2 MeSH |
| 650 | _ | 2 | |a Diagnosis, Differential |2 MeSH |
| 650 | _ | 2 | |a Receptors, Chimeric Antigen |2 MeSH |
| 700 | 1 | _ | |a Baz, Anna Magdalena |b 1 |
| 700 | 1 | _ | |a Schmidt, Elena Nicola Charlotte |b 2 |
| 700 | 1 | _ | |a Bendella, Zeynep |0 P:(DE-2719)9003165 |b 3 |u dzne |
| 700 | 1 | _ | |a Clauberg, Ralf |b 4 |
| 700 | 1 | _ | |a Radbruch, Alexander |0 P:(DE-2719)9001861 |b 5 |u dzne |
| 700 | 1 | _ | |a Pröbstel, Anne-Katrin |0 P:(DE-2719)9003515 |b 6 |u dzne |
| 700 | 1 | _ | |a Bischof, Antje |0 P:(DE-2719)9003766 |b 7 |u dzne |
| 700 | 1 | _ | |a Möhn, Nora |b 8 |
| 700 | 1 | _ | |a Wichtmann, Barbara Daria |0 P:(DE-2719)9003380 |b 9 |e Last author |u dzne |
| 773 | _ | _ | |a 10.1007/s00117-025-01541-y |g Vol. 66, no. 1, p. 59 - 66 |0 PERI:(DE-600)3120921-X |n 1 |p 59 - 66 |t Die Radiologie |v 66 |y 2026 |x 2731-7048 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/283219/files/DZNE-2026-00068_Restricted.pdf |
| 856 | 4 | _ | |u https://pub.dzne.de/record/283219/files/DZNE-2026-00068_Restricted.pdf?subformat=pdfa |x pdfa |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 3 |6 P:(DE-2719)9003165 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)9001861 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 6 |6 P:(DE-2719)9003515 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 7 |6 P:(DE-2719)9003766 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 9 |6 P:(DE-2719)9003380 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-18 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-18 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-18 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-18 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b RADIOLOGIE : 2022 |d 2024-12-18 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2024-12-18 |
| 920 | 1 | _ | |0 I:(DE-2719)5000075 |k AG Radbruch |l Clinical Neuroimaging |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a EDITORS |
| 980 | _ | _ | |a VDBINPRINT |
| 980 | _ | _ | |a I:(DE-2719)5000075 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::